| Ytd | -35.18% | |
| 1y | -22.25% |
| Open | 3.77 | Prev Close | 3.81 | Low | 3.62 | High | 3.93 | Mkt Cap | 102.45M |
| Vol | 1.30M | Avg Vol | 890.00K | EPS | -1.72 | P/E | N/A | Forward P/E | -3.31 |
| Beta | 2.29 | Short Ratio | 0.74 | Inst. Own | 38.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 4.57 | 200-d Avg | 6.12 | 1yr Est | 5.50 |
UNCY News
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that
A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on J
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud
Lead plaintiff deadlines are approaching in securities class actions filed on behalf of investors in
A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - October 28, 2026) - WHY: Rosen Law Firm, a global investor rig
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors abou
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and P
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SueWallSt alerts investors in Unicycive Therapeutics, In
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
LOS ANGELES, Oct. 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Unicycive
Class action covers investors who bought Unicycive Therapeutics, Inc. securities between December 29
A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer
San Diego, California--(Newsfile Corp. - October 26, 2026) - Shareholder rights law firm Robbins LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - October 26, 2026) - WHY: Rosen Law Firm, a global investor rig
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud
New York, New York--(Newsfile Corp. - October 26, 2026) - Kaplan Fox & Kilsheimer LLP announces that
New York, New York--(Newsfile Corp. - October 25, 2026) - WHY: Rosen Law Firm, a global investor rig
NEW YORK, Oct. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,
Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities
NEW YORK, Oct. 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, remi
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: New York, N.Y., October 23, 2026.
What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wol
Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 2
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinic
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
The Company anticipates United States Food and Drug Administration (FDA) acceptance of the NDA with
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Guggenheim analyst Vamil Divan maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowe
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.06) per share which beat the a
Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative
Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Unicycive Therapeutics (NASDAQ:U
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
B. Riley Securities analyst Mayank Mamtani maintains Unicycive Therapeutics (NASDAQ:UNCY) with a
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%.
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again o
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therap